Stockscreener 앱 받기
54.23
7.62%
3.84
시간 외 거래:
54.23
전일 마감가:
$50.39
열려 있는:
$51.84
하루 거래량:
4.60M
Relative Volume:
1.95
시가총액:
$6.76B
수익:
$692.26M
순이익/손실:
$-512.41M
주가수익비율:
-12.79
EPS:
-4.24
순현금흐름:
$-274.36M
1주 성능:
+30.93%
1개월 성능:
+6.71%
6개월 성능:
+21.95%
1년 성능:
+79.15%
1일 변동 폭
$51.44
$54.62
1주일 범위
$41.19
$54.62
52주 변동 폭
$20.14
$54.62
가든트헬스 Stock (GH) Company Profile
명칭
Guardant Health Inc
전화
855-698-8887
주소
3100 HANOVER STREET, PALO ALTO
GH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
54.23 | 5.56B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
460.72 | 169.53B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
200.56 | 139.75B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
658.06 | 49.94B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
114.62 | 32.16B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
179.86 | 30.17B | 15.50B | 1.33B | 2.16B | 7.34 |
가든트헬스 Stock (GH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-06-28 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-24 | 재개 | Craig Hallum | Buy |
| 2023-12-14 | 개시 | Guggenheim | Neutral |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-13 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-09-27 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-05-05 | 개시 | UBS | Buy |
| 2023-03-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-11-01 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | 개시 | Craig Hallum | Buy |
| 2022-10-06 | 개시 | Stephens | Overweight |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-06-03 | 개시 | Piper Sandler | Overweight |
| 2022-04-28 | 재개 | BTIG Research | Buy |
| 2022-02-24 | 재확인 | Canaccord Genuity | Buy |
| 2022-02-24 | 재확인 | Citigroup | Buy |
| 2022-02-24 | 재확인 | Cowen | Outperform |
| 2022-02-24 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-24 | 재확인 | SVB Leerink | Outperform |
| 2022-02-24 | 재확인 | Stifel | Buy |
| 2022-02-24 | 재확인 | Wells Fargo | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-05-25 | 개시 | Wells Fargo | Overweight |
| 2021-01-11 | 개시 | Stifel | Buy |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-06-12 | 개시 | BTIG Research | Buy |
| 2020-02-21 | 개시 | Guggenheim | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-08-07 | 재확인 | Canaccord Genuity | Buy |
| 2019-04-16 | 개시 | Canaccord Genuity | Buy |
| 2019-04-10 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | 재확인 | BofA/Merrill | Neutral |
| 2018-10-29 | 개시 | BofA/Merrill | Neutral |
| 2018-10-29 | 개시 | JP Morgan | Overweight |
| 2018-10-29 | 개시 | William Blair | Outperform |
모두보기
가든트헬스 주식(GH)의 최신 뉴스
Exact Sciences Teams Up With Freenome to Take on Guardant Health in Colorectal Cancer Screening - MedCity News
Guardant Health Surges 7.62% on $250M Volume Despite 396th Market Activity Rank - AInvest
Guardant Health Surges 13% on 197% Volume Spike Ranks 269th in Market Activity - AInvest
Guardant Health stock hits 52-week high at 53.49 USD By Investing.com - Investing.com South Africa
Guardant Health stock hits 52-week high at 53.49 USD - Investing.com
Guardant Health Soars 17.2% on Q2 Earnings Beat - AInvest
Exact Sciences acquires rights to rival Freenome’s blood-based colon cancer test - statnews.com
Multi-Cancer Early Detection Market Set to Revolutionize Cancer Diagnosis by 2034 | Driven by Liquid Biopsy Innovations and AI Integration - PharmiWeb.com
The Oncology Institute, Inc. shares rise 3.94% intraday after American Cancer Society and Guardant Health partnership. - AInvest
American Cancer Society and Guardant Health Partner to Expand Cancer Screening Access and Advance Health Equity - Business Wire
Is It Too Late to Sell Guardant Health Inc.Intraday Trend Analysis for Fast Gains Released - beatles.ru
Why is Guardant Health Inc. stock attracting strong analyst attentionRobust financial gains - Jammu Links News
What drives Guardant Health Inc. stock priceUnlock daily market insights for better trades - Jammu Links News
What is the risk reward ratio of investing in Guardant Health Inc. stockExceptional market positioning - Jammu Links News
Should I hold or sell Guardant Health Inc. stock in 2025Maximize portfolio value with expert tips - Jammu Links News
What catalysts could drive Guardant Health Inc. stock higher in 2025Exceptional trading results - Jammu Links News
How volatile is Guardant Health Inc. stock compared to the marketHarness the power of proven investment plans - Jammu Links News
What institutional investors are buying Guardant Health Inc. stockSignificant capital appreciation - Jammu Links News
Does Guardant Health Inc. stock perform well during market downturnsUnlock powerful portfolio management tools - Jammu Links News
What is Guardant Health Inc. company’s growth strategyMarket-leading growth rates - Jammu Links News
Is Guardant Health Inc. a growth stock or a value stockRapid growth trajectories - Jammu Links News
What are Guardant Health Inc. company’s key revenue driversStrong return on assets - Jammu Links News
Is Guardant Health Inc. stock overvalued or undervaluedAchieve breakthrough performance with smart picks - Jammu Links News
How many analysts rate Guardant Health Inc. as a “Buy”Unlock powerful portfolio management tools - Jammu Links News
Guardant Health, Inc. (NASDAQ:GH) Q2 2025 Earnings Call Transcript - Insider Monkey
Guardant Health Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Guardant Health Reports Strong Q2 2025 Growth - The Globe and Mail
Guardant Health to Participate in the Canaccord Genuity 45th Annual Growth Conference - Yahoo Finance
Guardant Health Analysts Increase Their Forecasts After Stronger-Than-Expected Q2 Earnings - Benzinga
Guardant Health's Q2 2025: Unpacking Contradictions in Volume Growth, Medicaid Impact, and Market Strategy - AInvest
Guardant Health’s Strong Performance and Growth Potential Justify Buy Rating Despite V2 Data Delay Concerns - TipRanks
Scotiabank raises Guardant Health stock price target to $60 on strong results - Investing.com Australia
Top Analysts Recommend 3 Strong Buy Stocks: Apellis Pharmaceuticals, Guardant Health, and Silvaco Group - AInvest
Guardant Health Beat Wall Street Expectations And Raised Its Outlook - Finimize
Guardant Health 2025 Q2 Earnings Mixed Results as Net Loss Narrows - AInvest
Guardant Health (GH) Q2 Revenue Up 31% - The Motley Fool
Guardant Health Inc (GH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised ... - Yahoo Finance
Guardant Health Inc (GH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised ... By GuruFocus - Investing.com Canada
Guardant Health: Q2 Earnings Snapshot - CTPost
Guardant Health (GH): Navigating Growth, Margins, and Valuation in a Competitive Healthcare Innovation Landscape - AInvest
Earnings call transcript: Guardant Health beats Q2 2025 forecasts, shares rise By Investing.com - Investing.com South Africa
Earnings call transcript: Guardant Health beats Q2 2025 forecasts, shares rise - Investing.com Canada
Guardant Health (GH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Guardant Health (NASDAQ:GH) Beats Expectations in Strong Q2, Guides for Strong Full-Year Sales - TradingView
Guardant Health (GH) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Guardant Health Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Guardant Health Q2 2025 slides: revenue up 31%, raises full-year guidance - Investing.com
가든트헬스 (GH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.15%
자본화:
|
볼륨(24시간):